Avenir Wellness Solutions, Inc. Stocks

$ 0Last Updated 27.04.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 7893

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Avenir Wellness Solutions, Inc., through its subsidiary The Sera Labs, Inc., engages in the development of nutraceutical formulation and delivery technologies in novel dosage forms to improve efficacy and enhance wellness. It provides its products in beauty, health and wellness, and pet care categories under the Seratopical, Seratopical Revolution SeraLabs, and Nutri-Strips brand names. The company sells its products through drug and grocery chains, convenience stores, and mass retailers. It also offers its products under private label to retailers and multi-level marketers, as well as DTC, via online website orders, including opt-in subscriptions. The company was formerly known as CURE Pharmaceutical Holding Corp. and changed its name to Avenir Wellness Solutions, Inc. in October 2022. Avenir Wellness Solutions, Inc. was incorporated in 2014 and is headquartered in Sherman Oaks, California.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks